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Registries have enhanced our knowledge of a
variety of diseases, including idiopathic
pulmonary fibrosis (IPF). In their article
“Antifibrotic Drug Use in Patients with
IPF: Data from the IPF-PRO Registry” in
this issue of AnnalsATS, Salisbury and
colleagues (pp. 1413–1423) investigated
patterns of use of antifibrotic medications
in the United States (1). The authors found
that the majority of patients in the IPF-
PRO (IPF Prospective Outcomes) Registry
were receiving an approved medication
for IPF at enrollment. Treatment at
enrollment was associated with greater
disease severity, more compromised
quality of life, and the use of oxygen with
exertion. The study confirms that
physicians are more likely to prescribe
antifibrotic drugs to patients with
progressive IPF than to patients with
milder forms (2).
Registries have an essential role
in understanding disease and are
particularly important in rare conditions.
They facilitate the acquisition of new
knowledge about prevalence, risk factors,
and disease pathogenesis as well as patient
management and treatment responses.
They also allow more accurate real-life
data collection than standardized clinical
trials, which follow strict inclusion and
exclusion criteria. Currently, patients
included in clinical trials are often selected
to maximize significant outcomes. In
contrast, patients with IPF in registries
often include those with more severe
disease (3). Data from clinical trials are
thus not necessarily applicable to real-life
populations, especially when patients
do not meet the same inclusion and
exclusion criteria. Registries may also
provide data when randomized clinical
trials are not yet available. They could be
used as a future platform for clinical
studies that more closely represent real-
world settings, albeit often showing less
significant results for new drugs than trials
do. This approach has not been tested for
IPF yet.
Many IPF registries have been initiated
and were described in a recent publication
(3). Some registries collect data from
patients with IPF from a single country,
whereas others have been extended to
several countries. These registries vary in
the types of interstitial lung diseases that
are included, and others focus specifically
on individuals with IPF, with some already
exceeding several thousands of patients
(3). These registries complement data
from clinical trials, and investigators are
already using them to discover new
biological aspects and validate preliminary
results from smaller cohorts. Although
existing disease registries are important,
building and maintaining registries over a
longer period of time can be tremendously
challenging. Differences in diagnostic
approaches and methodology result in
substantial variability in the included
patients across registries. This is amplified
by changes in diagnosis over time (4, 5),
the stage at the time patients are enrolled,
and missing data (3).
Clinical data in registries should be
complemented by biorepositories and
imaging archives. Open access to such
data would allow accelerated research for
all scientists (6). Access to human lung
tissues through commercial entities or
through the Lung Tissue Resource
Consortium (U.S. National Heart, Lung,
and Blood Institute–funded consortium)
has demonstrated the feasibility of this
approach (6). The prospective collection
and storage of blood, cell, and lung
samples with longitudinal clinical
phenotyping generated from various
sources in a biorepository and linked
registry has been suggested (6). But the
collection of samples and imaging also
needs to be standardized to allow high-
quality data collection for research in a
larger cohort.
Large registries for rare diseases
have previously proven to be very
helpful. The European registry for cystic
fibrosis included in the project
EuroCareCF, which is funded by the
Sixth Framework Program of the
European Commission, has proven that
a large international registry is feasible
and useful but also faces considerable
challenges (7, 8). An international
registry for IPF has been proposed
repeatedly for more than a decade (9),
but successful implementation has been
elusive.
An attractive alternative to building
a new global registry might involve
merging existing data from current IPF
registries. However, merging data on
national and international levels can
be challenging because of differences
in data sets resulting in technical
incompatibility, legal issues, and stakeholder
conflicts of interests. Registries can have
a great variability in data collection
depending on the research question or
intent behind the registry’s development.
Other challenges include threats to
data quality based on retrospective
and prospective data acquisition;
changes in diagnostic definition over
time implicate different diagnostic
criteria for registries set up at different
time points and difficulties in merging
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various imaging data. Together, these
issues hinder the creation of a global
registry. Artificial intelligence has been
suggested to be used to overcome
problems of data incompatibility (10).
A call to unite efforts to form a
global registry with structured, defined,
and focused goals and a proposed plan
were made in 2014 (11). The suggested
implementation was planned for 5 years, but
still these efforts have yet to result in a global
registry. Another European initiative,
endorsed by the European Respiratory
Society, the so-called Ariane-IPF ERS
Clinical Research Collaboration project,
aims to establish a platform for existing and
new registries to share data and conduct
common studies (12). This project includes
a metaregistry, allowing subgroup and
propensity analysis, which require large
datasets.
All these efforts are time-consuming
and costly. Infrastructures and resources
for rare and new disease registries
should be put in place to facilitate
timely and coordinated prospective
data collection to improve patient care
for IPF and other diseases. Funding
needs to be available to conduct prospective
high-quality registries on any scale.
Public funding for registries is difficult
to obtain for various reasons (e.g., the
ultimate goal is not clearly enough
defined or too many outcomes are
considered). Therefore, many registries
rely on industry sponsors. It would be
most desirable to have federal or national
funding support for registries with
clear research questions. National and
international societies would also be ideal
partners to coordinate and support data
collection for registries on a global scale.
Coordinating efforts would reduce the
burden of administrative, regulatory, and
funding obstacles and would decrease the
number of registries that fail over time or do
not result in meaningful research output.
Common efforts are required to achieve
these goals.
A global registry would be helpful to
gain rapid standardized information about
new unexplored diseases, disease courses,
and disease outcomes. Although some
efforts in this direction have already been
undertaken, there is still a long way to go.
Important steps toward this goal have
already been made, and the enthusiasm of
leaders in the field and the continuous work
of all in this direction will help to achieve the
goal of a global IPF registry. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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